Archerdx, of Boulder, Colo., said it signed an agreement to develop and commercialize a next-generation sequencing-based oncology companion diagnostic (CDx) for Summit, N.J.-based Celgene Corp.’s investigational drug, CC-122, for indications in diffuse large B-cell lymphoma (DLBCL).